{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T03:55:42Z","timestamp":1787025342280,"version":"build-2736575974"},"reference-count":32,"publisher":"Oceanside Publications Inc.","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["allergy asthma proc"],"published-print":{"date-parts":[[2024,11,1]]},"abstract":"<jats:p>Patients and families living with food allergy may experience significant burdens, including social isolation, impaired quality of life, and anxiety. Allergists\/immunologists play a critical role in educating families living with food allergies about risk, particularly with regard to\n the rarity of fatal food allergy. Appropriate risk framing can greatly decrease the fear-based burden of disease. In 2024, an increasing complex fabric of food allergy treatments has emerged that includes oral immunotherapy (OIT), sublingual immunotherapy (SLIT), and omalizumab, with the promise\n of additional treatments, including epicutaneous immunotherapy and oral mucosal immunotherapy in the near future. Younger children may be most likely to benefit from OIT and SLIT, with some evidence that suggests the possibility of an immunomodulatory effect. Omalizumab, approved in 2024 for\n use in conjunction with strict avoidance, increases the threshold of reactivity before a moderate-to-severe reaction for many, but not all, patients. There is no evidence to date that omalizumab has an immunomodulatory effect, and young children treated with omalizumab monotherapy may bear\n a lost opportunity cost from possible immunomodulation would they have been treated with OIT or SLIT instead; however, within a shared decision-making paradigm, beyond label use of omalizumab may include treatment with OIT or SLIT. Fortunately, the co-evolution of shared decision-making with\n modern food allergy treatments will facilitate the critical preference-sensitive care that must be characteristic of all decisions surrounding active food allergy management.<\/jats:p>","DOI":"10.2500\/aap.2024.45.240059","type":"journal-article","created":{"date-parts":[[2024,11,8]],"date-time":"2024-11-08T23:32:18Z","timestamp":1731108738000},"page":"409-413","source":"Crossref","is-referenced-by-count":6,"title":["The use of biologics in food allergy management"],"prefix":"10.2500","volume":"45","author":[{"given":"Marcus S.","family":"Shaker","sequence":"first","affiliation":[{"name":"From the Section of Allergy and Immunology, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1355","reference":[{"key":"B1","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1016\/j.jaci.2020.01.017","article-title":"Anaphylaxis\u2013a 2020 practice parameter update, systematic review, and Grading of Recommendations, Assessment, Development and Evaluation (GRADE) analysis","volume":"145","author":"Shaker","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"B2","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.jaci.2013.08.016","article-title":"Anaphylaxis in America: the prevalence and characteristics of anaphylaxis in the United States","volume":"133","author":"Wood","year":"2014","journal-title":"J Allergy Clin Immunol"},{"key":"B3","doi-asserted-by":"crossref","first-page":"3","DOI":"10.2500\/jfa.2023.5.230001","article-title":"Shared decision making, communicating risk, and food allergy in 2023","volume":"5","author":"Shaker","year":"2023","journal-title":"J Food Allergy"},{"key":"B4","doi-asserted-by":"crossref","first-page":"2481","DOI":"10.1016\/j.jaip.2024.06.023","article-title":"The cost-effectiveness of omalizumab for treatment of food allergy","volume":"12","author":"Shaker","year":"2024","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B5","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1001\/jamapediatrics.2013.2376","article-title":"The economic impact of childhood food allergy in the United States","volume":"167","author":"Gupta","year":"2013","journal-title":"JAMA Pediatr"},{"key":"B6","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.anai.2020.01.004","article-title":"Commercial claims costs related to health care resource use associated with a diagnosis of peanut allergy","volume":"124","author":"Shaker","year":"2020","journal-title":"Ann Allergy Asthma Immunol"},{"key":"B7","doi-asserted-by":"crossref","first-page":"3276","DOI":"10.1016\/j.jaip.2022.08.011","article-title":"The impact of allergy specialty care on health care utilization among peanut allergy children in the United States","volume":"10","author":"Greenhawt","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B8","doi-asserted-by":"crossref","first-page":"e10\u2013e17","DOI":"10.1542\/peds.2012-1180","article-title":"Child and parental reports of bullying in a consecutive sample of children with food allergy","volume":"131","author":"Shemesh","year":"2013","journal-title":"Pediatrics"},{"key":"B9","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.jaip.2014.05.001","article-title":"Longitudinal evaluation of food allergy-related bullying","volume":"2","author":"Annunziato","year":"2014","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B10","doi-asserted-by":"crossref","first-page":"e13695","DOI":"10.1111\/pai.13695","article-title":"Food-allergy-specific anxiety and distress in parents of children with food allergy: a systematic review","volume":"33","author":"Westwell-Roper","year":"2022","journal-title":"Pediatr Allergy Immunol"},{"key":"B11","doi-asserted-by":"crossref","first-page":"44","DOI":"10.2500\/aap.2017.38.4002","article-title":"Factors that determine parents' perception of their child's risk of life-threatening food-induced anaphylaxis","volume":"38","author":"Ogg","year":"2017","journal-title":"Allergy Asthma Proc"},{"key":"B12","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1016\/j.jaip.2017.06.031","article-title":"Fatal anaphylaxis: mortality rate and risk factors","volume":"5","author":"Turner","year":"2017","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B13","doi-asserted-by":"crossref","first-page":"100753","DOI":"10.1016\/j.waojou.2023.100753","article-title":"WAO consensus on DEfinition of Food Allergy SEverity (DEFASE)","volume":"16","author":"Arasi","year":"2023","journal-title":"World Allergy Organ J"},{"key":"B14","first-page":"2298","volume-title":"Allergic Diseases and Mental Health","volume":"12","author":"Conway","year":"2024"},{"key":"B15","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.anai.2020.01.029","article-title":"Engaging patient partners in state-of-the-art allergy care: finding balance when discussing risk","volume":"125","author":"Shaker","year":"2020","journal-title":"Ann Allergy Asthma Immunol"},{"key":"B16","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/S0140-6736(21)02390-4","article-title":"Efficacy and safety of oral immunotherapy in children aged 1\u20133 years with peanut allergy (the Immune Tolerance Network IMPACT trial): a randomised placebo-controlled study","volume":"399","author":"Jones","year":"2022","journal-title":"Lancet"},{"key":"B17","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.1016\/j.jaip.2024.04.043","article-title":"Real world adoption of peanut oral immunotherapy in infants and toddlers","volume":"12","author":"Mustafa","year":"2024","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B18","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1016\/j.jaip.2021.12.009","article-title":"Real-world peanut OIT in infants may be safer than non-infant preschool OIT and equally effective","volume":"10","author":"Soller","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B19","doi-asserted-by":"crossref","first-page":"2876","DOI":"10.1016\/j.jaip.2021.02.058","article-title":"The cost-effectiveness of preschool peanut oral immunotherapy in the real-world setting","volume":"9","author":"Shaker","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B20","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/j.jaip.2023.10.047","article-title":"Long-term clinical outcome of oral immunotherapy in adults with milk, peanut, and egg allergy: a pilot study","volume":"12","author":"Thomander","year":"2024","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B21","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1111\/all.15537","article-title":"Efficacy and safety of food allergy oral immunotherapy in adults","volume":"78","author":"Epstein-Rigbi","year":"2023","journal-title":"Allergy"},{"key":"B22","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.jaci.2023.08.032","article-title":"Desensitization and remission after peanut sublingual immunotherapy in 1- to 4-year-old peanut-allergic children: a randomized, placebo-controlled trial","volume":"153","author":"Kim","year":"2024","journal-title":"J Allergy Clin Immunol"},{"key":"B23","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1056\/NEJMoa022613","article-title":"Effect of anti-IgE therapy in patients with peanut allergy","volume":"348","author":"Leung","year":"2003","journal-title":"N Engl J Med"},{"key":"B24","article-title":"How Genentech, Novartis stifled a promising drug"},{"key":"B25","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1016\/j.jaci.2011.01.051","article-title":"A phase II, randomized, double-blind, parallel-group, placebo-controlled oral food challenge trial of Xolair (omalizumab) in peanut allergy","volume":"127","author":"Sampson","year":"2011","journal-title":"J Allergy Clin Immunol"},{"key":"B26","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1111\/cea.13469","article-title":"Individually dosed omalizumab facilitates peanut oral immunotherapy in peanut allergic adolescents","volume":"49","author":"Brandstr\u00f6m","year":"2019","journal-title":"Clin Exp Allergy"},{"key":"B27","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1016\/j.jaip.2019.01.023","article-title":"Impact of omalizumab on food allergy in patients treated for asthma: a real-life study","volume":"7","author":"Fiocchi","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B28","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1710-1492-10-7","article-title":"Phase 1 results of safety and tolerability in a rush oral immunotherapy protocol to multiple foods using omalizumab","volume":"10","author":"Begin","year":"2014","journal-title":"Allergy Asthma Clin Immunol"},{"key":"B29","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1016\/j.jaci.2015.10.005","article-title":"A randomized, double-blind, placebo-controlled study of omalizumab combined with oral immunotherapy for the treatment of cow's milk allergy","volume":"137","author":"Wood","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"B30","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1016\/j.jaip.2022.11.036","article-title":"Omalizumab in IgE-mediated food allergy: a systematic review and meta-analysis","volume":"11","author":"Zuberbier","year":"2023","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B31","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1056\/NEJMoa2312382","article-title":"Omalizumab for the treatment of multiple food allergies","volume":"390","author":"Wood","year":"2024","journal-title":"N Engl J Med"},{"key":"B32","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1016\/j.jaip.2024.02.039","article-title":"Pharmacoequity and biologics in the allergy clinic: providing the right care, at the right time, every time, to everyone","volume":"12","author":"Conway","year":"2024","journal-title":"J Allergy Clin Immunol Pract"}],"container-title":["Allergy and Asthma Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ingentaconnect.com\/content\/ocean\/aap\/2024\/00000045\/00000006\/art00010","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,8]],"date-time":"2024-11-08T23:34:38Z","timestamp":1731108878000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ingentaconnect.com\/content\/10.2500\/aap.2024.45.240059"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,1]]},"references-count":32,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,11,1]]}},"alternative-id":["1088-5412(20241101)45:6L.409;1-"],"URL":"https:\/\/doi.org\/10.2500\/aap.2024.45.240059","relation":{},"ISSN":["1088-5412"],"issn-type":[{"value":"1088-5412","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11,1]]}}}